Analysts forecast that Endo International PLC (NASDAQ:ENDP) will report $842.14 million in sales for the current fiscal quarter, according to Zacks. Six analysts have issued estimates for Endo International PLC’s earnings. The highest sales estimate is $879.80 million and the lowest is $804.00 million. Endo International PLC posted sales of $920.89 million in the same quarter last year, which would indicate a negative year-over-year growth rate of 8.6%. The firm is scheduled to issue its next earnings report before the market opens on Tuesday, August 8th.

According to Zacks, analysts expect that Endo International PLC will report full-year sales of $842.14 million for the current fiscal year, with estimates ranging from $3.51 billion to $3.61 billion. For the next financial year, analysts expect that the company will post sales of $3.31 billion per share, with estimates ranging from $3.13 billion to $3.45 billion. Zacks’ sales averages are a mean average based on a survey of research firms that follow Endo International PLC.

Endo International PLC (NASDAQ:ENDP) last posted its quarterly earnings results on Tuesday, May 9th. The company reported $1.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.10 by $0.13. Endo International PLC had a negative net margin of 82.93% and a positive return on equity of 25.32%. The business had revenue of $1.04 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same quarter last year, the firm posted $1.08 EPS. Endo International PLC’s revenue was up 7.7% compared to the same quarter last year.

A number of equities research analysts recently issued reports on ENDP shares. Royal Bank Of Canada set a $15.00 price target on Endo International PLC and gave the stock a “hold” rating in a research note on Saturday, April 8th. Canaccord Genuity reissued a “hold” rating and set a $14.00 price target on shares of Endo International PLC in a research note on Tuesday, April 11th. Mizuho reissued a “buy” rating and set a $18.00 price target (up from $17.00) on shares of Endo International PLC in a research note on Thursday, April 13th. Vetr lowered Endo International PLC from a “strong-buy” rating to a “hold” rating and set a $11.34 price target for the company. in a research note on Thursday, April 27th. Finally, BMO Capital Markets reissued a “hold” rating and set a $15.00 price target on shares of Endo International PLC in a research note on Monday, May 1st. Two analysts have rated the stock with a sell rating, sixteen have assigned a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $17.33.

Shares of Endo International PLC (NASDAQ ENDP) opened at 12.08 on Thursday. Endo International PLC has a 52-week low of $9.70 and a 52-week high of $24.93. The company has a 50-day moving average of $11.75 and a 200 day moving average of $12.04. The firm’s market cap is $2.70 billion.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Oakbrook Investments LLC increased its position in shares of Endo International PLC by 8.2% in the second quarter. Oakbrook Investments LLC now owns 17,100 shares of the company’s stock valued at $191,000 after buying an additional 1,300 shares during the period. Nisa Investment Advisors LLC acquired a new position in shares of Endo International PLC during the second quarter valued at $507,000. James Investment Research Inc. acquired a new position in shares of Endo International PLC during the second quarter valued at $113,000. Meeder Asset Management Inc. increased its position in shares of Endo International PLC by 1.4% in the second quarter. Meeder Asset Management Inc. now owns 48,699 shares of the company’s stock valued at $544,000 after buying an additional 677 shares during the period. Finally, Capstone Asset Management Co. increased its position in shares of Endo International PLC by 3.1% in the second quarter. Capstone Asset Management Co. now owns 32,035 shares of the company’s stock valued at $358,000 after buying an additional 960 shares during the period. Hedge funds and other institutional investors own 93.17% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This story was first reported by American Banking News and is the property of of American Banking News. If you are viewing this story on another domain, it was illegally copied and reposted in violation of US and international trademark and copyright legislation. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/07/20/endo-international-plc-endp-expected-to-post-quarterly-sales-of-842-14-million.html.

Endo International PLC Company Profile

Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.

Get a free copy of the Zacks research report on Endo International PLC (ENDP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Endo International PLC (NASDAQ:ENDP)

Receive News & Ratings for Endo International PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International PLC and related companies with MarketBeat.com's FREE daily email newsletter.